Avitas Wealth Management LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Avitas Wealth Management LLC bought a new stake in Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,337 shares of the company’s stock, valued at approximately $3,925,000. Johnson & Johnson makes up 1.1% of Avitas Wealth Management LLC’s holdings, making the stock its 23rd largest position.

Several other institutional investors also recently modified their holdings of JNJ. Virtus ETF Advisers LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter worth $25,000. Krane Funds Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter worth $26,000. Crewe Advisors LLC lifted its stake in shares of Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares during the period. Permanens Capital L.P. lifted its stake in shares of Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after acquiring an additional 100 shares during the period. Finally, Personal Wealth Partners acquired a new stake in shares of Johnson & Johnson in the 2nd quarter worth $73,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

Shares of JNJ opened at $129.20 on Wednesday. The company has a 50-day simple moving average of $130.47 and a 200-day simple moving average of $134.56. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $337.02 billion, a PE ratio of 15.79, a P/E/G ratio of 2.16 and a beta of 0.69. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.54%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.05 EPS. On average, research analysts anticipate that Johnson & Johnson will post 8.65 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.94%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

Several analysts have recently commented on the stock. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Friday, October 11th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research note on Wednesday, October 16th. Bank of America restated a “hold” rating and issued a $150.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Finally, Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $151.18.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: How to execute a trade ex-dividend strategy?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.